PVCT
Provectus Biopharmaceuticals, Inc.
Price Chart
Latest Quote
$0.06
+0.00 (+0.00%)
Current Price
| Previous Close | $0.06 |
| Open | $0.06 |
| Day High | $0.06 |
| Day Low | $0.06 |
| Volume | 100,887 |
Stock Information
| Shares Outstanding | 420.28M |
| Total Debt | $2.77M |
| Cash Equivalents | $224K |
| Revenue | $57K |
| Net Income | $-5.58M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $26.06M |
| EPS (TTM) | $-0.01 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $28.51M |
| Sales | $57K |
| Income | $-5.58M |
| Book/sh | $-0.02 |
| Cash/sh | $0.00 |
| Employees | 6 |
Financial Ratios
| Quick Ratio | 0.03 |
| Current Ratio | 0.06 |
Returns & Margins
| ROA | -501.90% |
| Operating Margin | -8688.64% |
Ownership
| Insider Ownership | 7.79% |
| Institutional Ownership | 0.05% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 453.33 |
| P/B | -3.87 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.06 |
| SMA50 | $0.06 |
| SMA200 | $0.06 |
| RSI | 45.45 |
| ATR | 0.0050 |
| Shares Float | 387.95M |
| Short Float | 0.78% |
| Short Ratio | 0.47 |
| Volatility | 0.84 |
| Rel Volume | 0.19 |
Performance History
| Week | -8.82% |
| Month | -6.06% |
| Quarter | +14.81% |
| 6 Months | -1.59% |
| YTD | -3.13% |
| Year | -21.52% |
| 3 Years | -47.90% |
| 5 Years | -10.14% |
| 10 Years | -82.78% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.06 | 20,400 |
| 2026-06-17 | $0.06 | 122,000 |
| 2026-06-16 | $0.06 | 125,900 |
| 2026-06-15 | $0.06 | 10,300 |
| 2026-06-12 | $0.06 | 155,400 |
| 2026-06-11 | $0.07 | 17,000 |
| 2026-06-10 | $0.07 | 51,500 |
| 2026-06-09 | $0.07 | 10,100 |
| 2026-06-08 | $0.06 | 17,000 |
| 2026-06-05 | $0.06 | 18,800 |
| 2026-06-04 | $0.06 | 72,200 |
| 2026-06-03 | $0.07 | 78,900 |
| 2026-06-02 | $0.06 | 379,400 |
| 2026-06-01 | $0.07 | 194,100 |
| 2026-05-29 | $0.06 | 66,700 |
| 2026-05-28 | $0.06 | 54,800 |
| 2026-05-27 | $0.06 | 463,300 |
| 2026-05-26 | $0.06 | 111,800 |
| 2026-05-22 | $0.06 | 91,600 |
| 2026-05-21 | $0.07 | 85,100 |
| 2026-05-20 | $0.07 | 67,800 |
| 2026-05-19 | $0.07 | 376,500 |
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and breast cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It also has collaboration agreement with Bascom Palmer Eye Institute, and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $239,073 | $216,214 | $163,691 | $961,698 |
| Total Expenses | $4,531,593 | $2,925,477 | $3,428,379 | $4,667,334 |
| Rent Expense Supplemental | $19,314 | $19,134 | $23,196 | $31,055 |
| Other Income Expense | $8,529 | $39,923 | $37,387 | $89,489 |
| Other Non Operating Income Expenses | $9,320 | $15,696 | $36,954 | $31,315 |
| Net Non Operating Interest Income Expense | $-239,073 | $-216,214 | $-163,691 | $-961,698 |
| Interest Expense Non Operating | $239,073 | $216,214 | $163,691 | $961,698 |
| Operating Expense | $4,531,593 | $2,925,477 | $3,428,379 | $4,667,334 |
| Other Operating Expenses | $-617,140 | $-557,710 | $-989,042 | - |
| General And Administrative Expense | $3,147,744 | $1,732,085 | $2,024,624 | $2,054,759 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,762,137 | $-3,101,768 | $-3,554,683 | $-5,539,543 |
| Net Interest Income | $-239,073 | $-216,214 | $-163,691 | $-961,698 |
| Normalized Income | $-4,761,346 | $-3,125,995 | $-3,555,116 | $-5,597,717 |
| Net Income From Continuing And Discontinued Operation | $-4,762,137 | $-3,101,768 | $-3,554,683 | $-5,539,543 |
| Total Operating Income As Reported | $-4,532,384 | $-2,901,250 | $-3,427,946 | $-4,672,254 |
| Net Income Common Stockholders | $-4,762,137 | $-3,101,768 | $-3,554,683 | $-5,539,543 |
| Net Income | $-4,762,137 | $-3,101,768 | $-3,554,683 | $-5,539,543 |
| Net Income Including Noncontrolling Interests | $-4,762,137 | $-3,101,768 | $-3,554,683 | $-5,539,543 |
| Net Income Continuous Operations | $-4,762,137 | $-3,101,768 | $-3,554,683 | $-5,539,543 |
| Pretax Income | $-4,762,137 | $-3,101,768 | $-3,554,683 | $-5,539,543 |
| Special Income Charges | $-576,908 | $-387,189 | $0 | $63,094 |
| Operating Income | $-4,531,593 | $-2,925,477 | $-3,428,379 | $-4,667,334 |
| Depreciation Amortization Depletion Income Statement | $1,862 | $1,862 | $3,437 | $4,218 |
| Depreciation And Amortization In Income Statement | $1,862 | $1,862 | $3,437 | $4,218 |
| Depreciation Income Statement | $1,862 | $1,862 | $3,437 | $4,218 |
| Interest Income | - | - | - | $4 |
| Interest Income Non Operating | - | - | - | $4 |
| Per Share | ||||
| Diluted EPS | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Basic EPS | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,515,116 | $-2,900,860 | $-3,380,530 | $-4,623,154 |
| Total Unusual Items | $-791 | $24,227 | $433 | $58,174 |
| Total Unusual Items Excluding Goodwill | $-791 | $24,227 | $433 | $58,174 |
| Reconciled Depreciation | $7,157 | $8,921 | $10,895 | $12,865 |
| EBITDA (Bullshit earnings) | $-4,515,907 | $-2,876,633 | $-3,380,097 | $-4,564,980 |
| EBIT | $-4,523,064 | $-2,885,554 | $-3,390,992 | $-4,577,845 |
| Diluted Average Shares | $419,810,059 | $419,508,146 | $419,470,338 | $408,223,004 |
| Basic Average Shares | $419,810,059 | $419,508,146 | $419,470,338 | $408,223,004 |
| Diluted NI Availto Com Stockholders | $-4,762,137 | $-3,101,768 | $-3,554,683 | $-5,539,543 |
| Other Special Charges | $576,908 | $387,189 | $521,632 | $-63,094 |
| Gain On Sale Of Security | $-791 | $24,227 | $433 | $-4,920 |
| Other Taxes | $-9,320 | $-15,696 | $-36,954 | $-31,315 |
| Research And Development | $1,999,127 | $1,749,240 | $2,389,360 | $2,608,357 |
| Selling General And Administration | $3,147,744 | $1,732,085 | $2,024,624 | $2,054,759 |
| Other Gand A | $1,155,781 | $897,420 | $1,183,754 | $1,245,814 |
| Insurance And Claims | $168,644 | $179,846 | $182,897 | $161,992 |
| Rent And Landing Fees | $19,314 | $19,134 | $23,196 | $31,055 |
| Salaries And Wages | $1,804,005 | $635,685 | $634,777 | $615,898 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-5,959,332 | $-7,593,351 | $-6,228,510 | $-4,187,280 |
| Total Assets | $1,006,259 | $1,448,843 | $2,037,246 | $3,513,356 |
| Total Non Current Assets | $29,487 | $84,046 | $138,064 | $71,399 |
| Current Assets | $976,772 | $1,364,797 | $1,899,182 | $3,441,957 |
| Other Current Assets | $236,383 | $337,522 | $467,081 | $329,908 |
| Current Deferred Assets | $1,596 | $1,596 | - | - |
| Current Deferred Taxes Assets | $1,596 | $1,596 | - | - |
| Restricted Cash | $182,284 | $950,223 | $1,410,102 | $2,423,958 |
| Prepaid Assets | $249,067 | $335,926 | - | $329,908 |
| Receivables | $0 | $476 | $394 | $5,107 |
| Accounts Receivable | $0 | $476 | $394 | $5,107 |
| Cash Cash Equivalents And Short Term Investments | $307,442 | $76,576 | $21,605 | $682,984 |
| Cash And Cash Equivalents | $307,442 | $76,576 | $21,605 | $682,984 |
| Cash Financial | $307,442 | $76,576 | $21,605 | - |
| Debt | ||||
| Net Debt | $2,852,021 | $2,876,239 | $2,045,289 | $1,015,468 |
| Total Debt | $3,184,762 | $3,026,191 | $2,184,692 | $1,744,069 |
| Long Term Debt And Capital Lease Obligation | $0 | $25,299 | $73,376 | $0 |
| Current Debt And Capital Lease Obligation | $3,184,762 | $3,000,892 | $2,111,316 | $1,744,069 |
| Current Debt | $3,159,463 | $2,952,815 | $2,066,894 | $1,698,452 |
| Other Current Borrowings | $2,953,000 | $2,675,000 | $1,827,500 | $1,460,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,975,484 | $9,042,194 | $8,265,756 | $7,700,636 |
| Total Non Current Liabilities Net Minority Interest | $0 | $25,299 | $73,376 | $0 |
| Current Liabilities | $6,975,484 | $9,016,895 | $8,192,380 | $7,700,636 |
| Current Deferred Liabilities | $336,108 | $953,248 | $1,510,958 | $2,500,000 |
| Current Notes Payable | $206,463 | $277,815 | $239,394 | $238,452 |
| Payables And Accrued Expenses | $3,323,515 | $4,969,770 | $4,501,029 | $3,306,567 |
| Interest Payable | $172,687 | $146,428 | $71,836 | $16,622 |
| Payables | $1,106,551 | $1,675,891 | $2,094,258 | $1,287,459 |
| Accounts Payable | $1,106,551 | $1,675,891 | $2,094,258 | $1,287,459 |
| Other Current Liabilities | - | - | - | $150,000 |
| Equity | ||||
| Common Stock Equity | $-5,973,395 | $-7,616,085 | $-6,250,630 | $-4,208,872 |
| Preferred Stock Equity | $14,063 | $22,734 | $22,120 | $21,592 |
| Total Equity Gross Minority Interest | $-5,969,225 | $-7,593,351 | $-6,228,510 | $-4,187,280 |
| Stockholders Equity | $-5,959,332 | $-7,593,351 | $-6,228,510 | $-4,187,280 |
| Gains Losses Not Affecting Retained Earnings | $-60,741 | $-60,165 | $-35,679 | $-34,467 |
| Other Equity Adjustments | $-60,741 | $-60,165 | $-35,679 | $-34,467 |
| Retained Earnings | $-257,422,961 | $-252,690,409 | $-249,588,641 | $-246,033,958 |
| Other | ||||
| Ordinary Shares Number | $420,279,879 | $419,522,119 | $419,497,119 | $419,447,119 |
| Share Issued | $420,279,879 | $419,522,119 | $419,497,119 | $419,447,119 |
| Tangible Book Value | $-5,973,395 | $-7,616,085 | $-6,250,630 | $-4,208,872 |
| Invested Capital | $-2,813,932 | $-4,663,270 | $-4,183,736 | $-2,510,420 |
| Working Capital | $-5,998,712 | $-7,652,098 | $-6,293,198 | $-4,258,679 |
| Capital Lease Obligations | $25,299 | $73,376 | $117,798 | $45,617 |
| Total Capitalization | $-5,959,332 | $-7,593,351 | $-6,228,510 | $-4,187,280 |
| Minority Interest | $-9,893 | $0 | - | - |
| Additional Paid In Capital | $251,090,027 | $244,714,967 | $242,954,193 | $241,440,106 |
| Capital Stock | $434,343 | $442,256 | $441,617 | $441,039 |
| Common Stock | $420,280 | $419,522 | $419,497 | $419,447 |
| Preferred Stock | $14,063 | $22,734 | $22,120 | $21,592 |
| Long Term Capital Lease Obligation | $0 | $25,299 | $73,376 | $0 |
| Current Deferred Revenue | $336,108 | $953,248 | $1,510,958 | $2,500,000 |
| Current Capital Lease Obligation | $25,299 | $48,077 | $44,422 | $45,617 |
| Pensionand Other Post Retirement Benefit Plans Current | $131,099 | $92,985 | $69,077 | - |
| Current Accrued Expenses | $2,216,964 | $3,293,879 | $2,406,771 | $2,019,108 |
| Net PPE | $29,487 | $84,046 | $138,064 | $71,399 |
| Accumulated Depreciation | $-118,151 | $-110,994 | $-102,073 | $-91,178 |
| Gross PPE | $147,638 | $195,040 | $240,137 | $162,577 |
| Machinery Furniture Equipment | $123,014 | $123,014 | $123,014 | $123,014 |
| Buildings And Improvements | $24,624 | $72,026 | $117,123 | $39,563 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | $0 | - | - |
| Dueto Related Parties Current | - | $2,330,589 | $1,945,589 | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,284,091 | $-2,571,978 | $-3,041,472 | $-1,013,304 |
| Operating Activities | ||||
| Operating Cash Flow | $-3,284,091 | $-2,571,978 | $-3,041,472 | $-1,013,304 |
| Cash Flow From Continuing Operating Activities | $-3,284,091 | $-2,571,978 | $-3,041,472 | $-1,013,304 |
| Operating Gains Losses | - | - | - | $-63,094 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $300,000 | $0 | $0 | $150,000 |
| Financing Cash Flow | $2,747,865 | $2,191,555 | $1,367,841 | $4,024,046 |
| Cash Flow From Continuing Financing Activities | $2,747,865 | $2,191,555 | $1,367,841 | $4,024,046 |
| Net Common Stock Issuance | $300,000 | $0 | - | - |
| Common Stock Issuance | $300,000 | $0 | - | - |
| Net Preferred Stock Issuance | - | - | $0 | $150,000 |
| Preferred Stock Issuance | - | - | $0 | $150,000 |
| Other | ||||
| Repayment Of Debt | $-405,135 | $-283,445 | $-259,659 | $-248,177 |
| Issuance Of Debt | $2,853,000 | $2,475,000 | $1,627,500 | $3,160,000 |
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $489,726 | $1,026,799 | $1,431,707 | $3,106,942 |
| Beginning Cash Position | $1,026,799 | $1,431,707 | $3,106,942 | $97,231 |
| Effect Of Exchange Rate Changes | $-847 | $-24,485 | $-1,604 | $-1,031 |
| Changes In Cash | $-536,226 | $-380,423 | $-1,673,631 | $3,010,742 |
| Net Issuance Payments Of Debt | $2,447,865 | $2,191,555 | $1,367,841 | $2,911,823 |
| Net Short Term Debt Issuance | $2,447,865 | $2,191,555 | $1,367,841 | $2,911,823 |
| Short Term Debt Payments | $-405,135 | $-283,445 | $-259,659 | $-248,177 |
| Short Term Debt Issuance | $2,853,000 | $2,475,000 | $1,627,500 | $3,160,000 |
| Change In Working Capital | $142,711 | $472,922 | $446,408 | $4,471,522 |
| Change In Other Working Capital | $-617,140 | $-557,710 | $-989,042 | $2,500,000 |
| Change In Other Current Liabilities | $-48,077 | $-44,422 | $-58,262 | $-83,549 |
| Change In Payables And Accrued Expense | $723,205 | $623,711 | $1,366,317 | $1,790,563 |
| Change In Accrued Expense | $1,292,362 | $1,042,081 | $559,244 | $1,459,415 |
| Change In Interest Payable | $225,481 | $205,655 | $156,854 | $956,834 |
| Change In Payable | $-569,157 | $-418,370 | $807,073 | $331,148 |
| Change In Account Payable | $-569,157 | $-418,370 | $807,073 | $331,148 |
| Change In Prepaid Assets | $84,247 | $451,425 | $122,914 | $265,957 |
| Change In Receivables | $476 | $-82 | $4,481 | $-1,449 |
| Other Non Cash Items | $47,402 | $45,097 | $52,883 | $81,258 |
| Stock Based Compensation | $1,280,776 | $2,850 | $3,025 | $23,688 |
| Depreciation Amortization Depletion | $7,157 | $8,921 | $10,895 | $12,865 |
| Depreciation And Amortization | $7,157 | $8,921 | $10,895 | $12,865 |
| Depreciation | $7,157 | $8,921 | $10,895 | $12,865 |
| Net Income From Continuing Operations | $-4,762,137 | $-3,101,768 | $-3,554,683 | $-5,539,543 |
| Proceeds From Stock Option Exercised | - | - | $0 | $962,223 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Amortization Cash Flow | - | - | - | $0 |
| Amortization Of Intangibles | - | - | - | $0 |
Fetched: 2026-02-02